WO2012051246A1 - Tapentadol hydrobromide and crystalline forms thereof - Google Patents

Tapentadol hydrobromide and crystalline forms thereof Download PDF

Info

Publication number
WO2012051246A1
WO2012051246A1 PCT/US2011/055893 US2011055893W WO2012051246A1 WO 2012051246 A1 WO2012051246 A1 WO 2012051246A1 US 2011055893 W US2011055893 W US 2011055893W WO 2012051246 A1 WO2012051246 A1 WO 2012051246A1
Authority
WO
WIPO (PCT)
Prior art keywords
tapentadol
hydrobromide
tapentadol hydrobromide
salt
crystalline
Prior art date
Application number
PCT/US2011/055893
Other languages
French (fr)
Inventor
Alexandre Mathieu
Original Assignee
Ratiopharm Gmbh
Teva Pharmaceuticals Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh, Teva Pharmaceuticals Usa, Inc. filed Critical Ratiopharm Gmbh
Publication of WO2012051246A1 publication Critical patent/WO2012051246A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention concerns the hydrobromide salt of Tapentadol, solid state forms of Tapentadol hydrobromide, processes for their preparation, and pharmaceutical
  • compositions comprising Tapentadol hydrobromde or a solid state form thereof.
  • Tapentadol is marketed under the trade name Nucynta for the treatment of moderate to severe pain.
  • EP 1390023 discloses pharmaceutical salts of 1- phenyl-3-dimethylamino-propane compounds and sugar substitutes.
  • International patent application publication no. WO2008/110323 discloses the salts of l-phenyl-3- dimemylamino-propane and their use in treating neuropathic pain.
  • Different salts of an active pharmaceutical ingredient may possess different properties. Such variations in the properties of different salts may provide a basis for improving formulation. Different salts of an active pharmaceutical ingredient may also give rise to a variety of polymorphs or crystalline forms.
  • Polymorphism the occurrence of different crystal forms, is a property of some molecules and molecular complexes.
  • a single molecule like Tapentadol and its salts, may give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviours (e.g., measured by capillary melting point, thermogravimetric analysis (TGA), or differential scanning calorimetry (DSC), as well as content of solvent in the polymorphic form), powder x-ray diffraction pattern (PXRD), infrared absorption and Raman fingerprints, and solid state NMR spectrum.
  • TGA thermogravimetric analysis
  • DSC differential scanning calorimetry
  • PXRD powder x-ray diffraction pattern
  • Raman fingerprints solid state NMR spectrum
  • polymorphs are distinct solids sharing the same molecular formula yet having distinct physical properties compared to other polymorphic forms of the same compound or complex.
  • the present invention provides a salt of Tapentadol, Tapentadol hydrobromide, isolated and solid state forms of Tapentadol hydrobromide, and provides pharmaceutical compositions comprising Tapentadol hydrobromide or at least one solid state form (or solid state forms) thereof, and at least one pharmaceutically acceptable excipient.
  • the solid state forms of Tapentadol hydrobromide include the hydrates and solvates of Tapentadol hydrobromide.
  • the invention further provides the use of Tapentadol hydrobromide, and the solid state forms described below for the manufacture of a medicament for the treatment of moderate to severe pain, and provides for a method of treatment of moderate to severe pain comprising administering a therapeutically effective dose of at least one of the solid state forms described herein to a person suffering from moderate to severe pain.
  • the invention provides a method for treating moderate to severe pain comprising administering the pharmaceutical composition comprising Tapentadol hydrobromide or at least one solid state form thereof and at least one pharmaceutically acceptable excipient.
  • Figure 1 shows a powder XRD pattern of Tapentadol hydrobromide.
  • Figure 2 shows a DSC thermogram of Tapentadol hydrobromide.
  • Figure 3 shows a powder XRD pattern of Tapentadol free base.
  • a crystal form may be referred to herein as being characterized by graphical data "as shown in,” or “as depicted in,” or “substantially as depicted in” a Figure.
  • Such data include, for example, powder X-ray diffractograms and solid state NMR spectra.
  • the skilled person will understand that such graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to factors such as variations in instrument response and variations in sample concentration and purity, which are well known to the skilled person. Nonetheless, the skilled person would readily be capable of comparing the graphical data in the Figure disclosed herein with graphical data generated for an unknown crystal form, and confirm whether the two sets of data are characterizing the same crystal form or two different crystal forms.
  • the crystal form characterized by the graphical data "as shown in,” or “as depicted in,” or “substantially as depicted in” a Figure disclosed herein includes a crystal form characterized by graphical data with small variations, which are well known to the skilled person, in comparison to the graphical data in the Figure.
  • a crystal form, crystalline form or polymorph may be referred to herein as pure or polymorphically pure, or substantially free of any other crystalline or polymorphic forms.
  • the expression “substantially free” will be understood to mean that the crystalline form contains 20% or less, 10% or less, 5% or less, 2% or less, or 1% or less of any other crystalline forms of the subject compound as measured, for example, by PXRD.
  • crystalline forms of Tapentadol salts described herein as substantially free of any other crystalline forms would be understood to contain greater than 80% (w/w), greater than 90% (w/w), greater than 95% (w/w), greater than 98% (w/w), or greater than 99% (w/w) of the subject crystalline form of Tapentadol salt. Accordingly, in some embodiments of the invention, the described crystalline form may contain from 1% to 20% (w/w), from 5% to 20% (w/w), or from 5% to 10% (w/w) of one or more other crystal forms of the same compound.
  • the present invention provides Tapentadol hydrobromide.
  • the Tapentadol hydrobromide of the present invention can be crystalline.
  • the present invention provides a crystalline form of Tapentadol hydrobromide characterized by data selected from: a powder XRD pattern with peaks at 9.9, 14.3, 15.3, 19.1 and 20.9 + 0.2° 2 ⁇ ; apowder XRD pattern substantially as depicted in Figure 1; a DSC thermogram substantially as depicted in Figure 2; and any combinations thereof.
  • a person skilled in the art would be able to characterize the above form by identifying one or more characteristic peaks in a powder X-ray diffraction analysis of that form.
  • the skilled person would be able to characterize the above form by selecting one or more characteristic peaks in the diffractogram provided in Figure 1.
  • the Tapentadol hydrobromide salt and its crystalline forms in the present invention have advantageous properties selected from at least one of: high crystallinity, solubility, dissolution rate, morphology, thermal and mechanical stability to polymorphic conversion and/or to dehydration, storage stability, low content of residual solvent, a lower degree of hygroscopicity, flowability, and advantageous processing and handling characteristics such as compressibility, and bulk density.
  • These properties may provide a basis for improving formulation, for example, by facilitating better processing or handling characteristics, improving the dissolution profile, or improving stability and shelf-life. They may also provide improvements to the final dosage form, for instance, if they serve to improve bioavailability, or shelf-live or storage etc.
  • the present invention further encompasses 1) a pharmaceutical composition comprising Tapentadol hydrobromide salt, or a composition comprising at least one solid state form of Tapentadol hydrobromide, as described above, and at least one
  • Tapentadol hydrobromide salt and its solid state forms to a subject in need of the treatment.
  • the pharmaceutical composition can be useful for preparing a medicament.
  • the present invention also provides Tapentadol hydrobromide salt or at least one of its solid state forms as described above for use as a medicament.
  • the Tapentadol hydrobromide and its crystalline forms of the present invention are useful for preparing different Tapentadol salts or Tapentadol free base.
  • the above described salt of Tapentadol, Tapentadol hydrobromide, and in particular the above described crystalline forms of Tapentadol hydrobromide can be used to prepare a pharmaceutical composition.
  • Such pharmaceutical compositions can be useful for treating pain, such as moderate to severe pain.
  • the samples were, if necessary, ground in an agate mortar and properly prepared (flatted surface in zO) on a specimen holder made from PMMA.
  • the samples were then analyzed on a Bruker-AXS D8 Advance powder X-ray diffractometer (Bruker-AXS, Düsseldorf, Germany).
  • the specimen holder was rotated in the zO plane at 20 rpm during measurement.
  • the measurement conditions were as follows: Radiation: Cu Ka of wavelength 1.54A , Source 40 kV / 40 mA, divergence slit 0.6 mm, detector: Vantec-1 anti- scattering slit 5.59 mm, detector slit 10.28 mm, start angle 3°2Theta, end angle 55°2Theta, Step 0.017° 2Theta.
  • Raw data were evaluated using the program EVA (Brulcer-AXS, Düsseldorf, Germany).
  • DSC Differential scanning calorimetry
  • a Mettler Toledo 822e DSC instrument was used to record the DSC curves. A sample amount of approx. 3.6 mg was placed in the calorimeter cell and heated from 30°C to 300°C with a rate of 10°C/min and a nitrogen flow of 50 ml/min.
  • Methoxy-Tapentadol hydrochloride (1 eq) was set free as Tapentadol base with 8 eq aqueous hydrobromic acid (47%) under reflux and subsequently sodium bicarbonate was added until pH 8 to 9 was reached. The solution was extracted several times with ethyl acetate. The combined organic phases were dried over sodium sulphate and distilled under reduced pressure.
  • Tapentadol base (0.52 g, 2.35 mmol) was dissolved in acetone (5 ml) at room temperature.
  • aqueous hydrobromic acid (47 wt.%, 1.21 g, 7 mmol) was added and the mixture was thereafter kept in the fumehood for 3 days in an open flask.
  • a solid precipitate formed and was separated out and filtered.
  • the solid material was washed with acetone, and dried overnight at 40 mbars and 40°C yielding tapentadol hydrobromide 0.38 g crystals (1.3 mmol, 53.5 %yield).
  • Example 4 Preparation of Tapentadol hydrochloride from Tapentadol hydrobromide Tapentadol hydrobromide was dissolved in acetone. Gaseous hydrogen chloride was bubbled through this clear solution, and the precipitate that formed was then filtered off.
  • Tapentadol base (1 eq) was dissolved in 2-butanone at room temperature. To this solution, 1 eq of trimethylsilyl bromide and leq of water were added. Tapentadol hydrobromide crystallized overnight in an open flask resultmg in a solid form, which did not undergo polymorphic conversion.
  • Tapentadol base (1 eq) was dissolved in 2-butanone at room temperature. To this solution, 1 eq of trimethylsilyl chloride and leq of water were added, whereupon Tapentadol hydrochloride crystallized. Depending on ambient conditions, either polymorphic Form A or Form B or mixtures thereof were obtained.
  • Tapentadol base (1 eq) was dissolved in an organic solvent selected from acetone, hexane, 2-butanone, diethylether, and butanol.
  • An acid (1 eq) selected from the table below was dissolved in the same solvent. The two solutions were combined and heated to about

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a salt of Tapentadol, Tapentadol liydrobromide, and crystalline forms of Tapentadol hydrobromide.

Description

TAPENTADOL HYDROBROMIDE AND CRYSTALLINE FORMS THEREOF
CROSS REFERENCE TO RELATED APPLICATION
The present patent application claims the benefit of U.S. Provisional Application No. 61/392,308 filed October 12, 2010, the disclosures of which are herein incorporated by reference.
FIELD OF INVENTION
The present invention concerns the hydrobromide salt of Tapentadol, solid state forms of Tapentadol hydrobromide, processes for their preparation, and pharmaceutical
compositions comprising Tapentadol hydrobromde or a solid state form thereof.
BACKGROUND OF THE INVENTION
Tapentadol, 3-[(lR,2R)-3-(dimethylamino)-l-ethyl-2-methylpropyl]phenol, has the formula:
Figure imgf000002_0001
Tapentadol is marketed under the trade name Nucynta for the treatment of moderate to severe pain.
Tapentadol hydrochloride, its synthesis, and its use as an analgesic are disclosed in U.S. patent no. 6,248,737. European patent nos. EP1612203 and EP0693475 disclose polymorphs of Tapentadol hydrochloride (Forms A and B, respectively). International patent application publication no. WO2009/071310 discloses three polymorphic forms of
Tapentadol free base. European patent no. EP 1390023 discloses pharmaceutical salts of 1- phenyl-3-dimethylamino-propane compounds and sugar substitutes. International patent application publication no. WO2008/110323 discloses the salts of l-phenyl-3- dimemylamino-propane and their use in treating neuropathic pain.
Different salts of an active pharmaceutical ingredient may possess different properties. Such variations in the properties of different salts may provide a basis for improving formulation. Different salts of an active pharmaceutical ingredient may also give rise to a variety of polymorphs or crystalline forms.
Polymorphism, the occurrence of different crystal forms, is a property of some molecules and molecular complexes. A single molecule, like Tapentadol and its salts, may give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviours (e.g., measured by capillary melting point, thermogravimetric analysis (TGA), or differential scanning calorimetry (DSC), as well as content of solvent in the polymorphic form), powder x-ray diffraction pattern (PXRD), infrared absorption and Raman fingerprints, and solid state NMR spectrum. The differences in physical properties have been used to distinguish polymorphic forms. One or more of these techniques may be used to distinguish different polymorphic forms of a compound. These techniques may also be used to quantify the amount of one or more crystalline forms in a mixture.
The differences in the physical properties of different salts and polymorphic forms results from the orientation and intermolecular interactions of adjacent molecules or complexes in the bulk solid. Accordingly, polymorphs are distinct solids sharing the same molecular formula yet having distinct physical properties compared to other polymorphic forms of the same compound or complex.
The discovery of new salts and polymorphic forms of Tapentadol can provide new ways to improve the synthesis and the characteristics of Tapentadol as an active
pharmaceutical ingredient.
SUMMARY OF THE INVENTION
The present invention provides a salt of Tapentadol, Tapentadol hydrobromide, isolated and solid state forms of Tapentadol hydrobromide, and provides pharmaceutical compositions comprising Tapentadol hydrobromide or at least one solid state form (or solid state forms) thereof, and at least one pharmaceutically acceptable excipient.
The solid state forms of Tapentadol hydrobromide include the hydrates and solvates of Tapentadol hydrobromide.
The invention further provides the use of Tapentadol hydrobromide, and the solid state forms described below for the manufacture of a medicament for the treatment of moderate to severe pain, and provides for a method of treatment of moderate to severe pain comprising administering a therapeutically effective dose of at least one of the solid state forms described herein to a person suffering from moderate to severe pain. The invention provides a method for treating moderate to severe pain comprising administering the pharmaceutical composition comprising Tapentadol hydrobromide or at least one solid state form thereof and at least one pharmaceutically acceptable excipient. BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows a powder XRD pattern of Tapentadol hydrobromide.
Figure 2 shows a DSC thermogram of Tapentadol hydrobromide.
Figure 3 shows a powder XRD pattern of Tapentadol free base. DETAILED DESCRIPTION OF THE INVENTION
A crystal form may be referred to herein as being characterized by graphical data "as shown in," or "as depicted in," or "substantially as depicted in" a Figure. Such data include, for example, powder X-ray diffractograms and solid state NMR spectra. The skilled person will understand that such graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to factors such as variations in instrument response and variations in sample concentration and purity, which are well known to the skilled person. Nonetheless, the skilled person would readily be capable of comparing the graphical data in the Figure disclosed herein with graphical data generated for an unknown crystal form, and confirm whether the two sets of data are characterizing the same crystal form or two different crystal forms. The crystal form characterized by the graphical data "as shown in," or "as depicted in," or "substantially as depicted in" a Figure disclosed herein includes a crystal form characterized by graphical data with small variations, which are well known to the skilled person, in comparison to the graphical data in the Figure.
A crystal form, crystalline form or polymorph may be referred to herein as pure or polymorphically pure, or substantially free of any other crystalline or polymorphic forms. As used herein in this context, the expression "substantially free" will be understood to mean that the crystalline form contains 20% or less, 10% or less, 5% or less, 2% or less, or 1% or less of any other crystalline forms of the subject compound as measured, for example, by PXRD. Thus, crystalline forms of Tapentadol salts described herein as substantially free of any other crystalline forms would be understood to contain greater than 80% (w/w), greater than 90% (w/w), greater than 95% (w/w), greater than 98% (w/w), or greater than 99% (w/w) of the subject crystalline form of Tapentadol salt. Accordingly, in some embodiments of the invention, the described crystalline form may contain from 1% to 20% (w/w), from 5% to 20% (w/w), or from 5% to 10% (w/w) of one or more other crystal forms of the same compound.
The present invention provides Tapentadol hydrobromide. The Tapentadol hydrobromide of the present invention can be crystalline.
For example, the present invention provides a crystalline form of Tapentadol hydrobromide characterized by data selected from: a powder XRD pattern with peaks at 9.9, 14.3, 15.3, 19.1 and 20.9 + 0.2° 2Θ; apowder XRD pattern substantially as depicted in Figure 1; a DSC thermogram substantially as depicted in Figure 2; and any combinations thereof.
A person skilled in the art would be able to characterize the above form by identifying one or more characteristic peaks in a powder X-ray diffraction analysis of that form. For example, the skilled person would be able to characterize the above form by selecting one or more characteristic peaks in the diffractogram provided in Figure 1.
Reaction of Tapentadol free base with an acid does not always produce a salt which could be isolated. This was an unexpected and surprising result. One skilled in the art would expect that reaction of the free base with an acid would produce a salt that could be isolated. For example, reaction of the free base with phosphoric acid produced the phosphate salt, but it became liquid a few seconds after separation from the reaction mixture. The sulphuric acid salt of Tapentadol could not be isolated. Reaction of the free base with other acids, such as fumaric acid, oxalic acid, maleic acid, succinic acid, methane sulfonic acid, ethane sulfonic acid, benzenesulfonic acid, benzoic acid, L-tartaric acid, acetic acid, citric acid and L-malic acid resulted in a bitumen. The reaction of Tapentadol free base with hydrobromic acid produced the hydrobromide salt of Tapentadol.
The Tapentadol hydrobromide salt and its crystalline forms in the present invention have advantageous properties selected from at least one of: high crystallinity, solubility, dissolution rate, morphology, thermal and mechanical stability to polymorphic conversion and/or to dehydration, storage stability, low content of residual solvent, a lower degree of hygroscopicity, flowability, and advantageous processing and handling characteristics such as compressibility, and bulk density. These properties may provide a basis for improving formulation, for example, by facilitating better processing or handling characteristics, improving the dissolution profile, or improving stability and shelf-life. They may also provide improvements to the final dosage form, for instance, if they serve to improve bioavailability, or shelf-live or storage etc.
The present invention further encompasses 1) a pharmaceutical composition comprising Tapentadol hydrobromide salt, or a composition comprising at least one solid state form of Tapentadol hydrobromide, as described above, and at least one
pharmaceutically acceptable excipient; 2) the use of any one or combination of the above- described Tapentadol hydrobromide salt and its solid state forms, in the manufacture of a pharmaceutical composition; and 3) a method of treating moderate to severe pain comprising administering an effective amount of any one or combination of the above-described
Tapentadol hydrobromide salt and its solid state forms to a subject in need of the treatment. The pharmaceutical composition can be useful for preparing a medicament. The present invention also provides Tapentadol hydrobromide salt or at least one of its solid state forms as described above for use as a medicament.
The Tapentadol hydrobromide and its crystalline forms of the present invention are useful for preparing different Tapentadol salts or Tapentadol free base. The above described salt of Tapentadol, Tapentadol hydrobromide, and in particular the above described crystalline forms of Tapentadol hydrobromide can be used to prepare a pharmaceutical composition. Such pharmaceutical compositions can be useful for treating pain, such as moderate to severe pain.
Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The invention is further defined by reference to the following examples describing in detail the preparation of the composition and processes of use of the invention. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention. The present invention is illustrated by the following examples, which should not be construed as limiting the scope of the present invention. EXAMPLES PXRD method
For PXRD characterisation, the samples were, if necessary, ground in an agate mortar and properly prepared (flatted surface in zO) on a specimen holder made from PMMA. The samples were then analyzed on a Bruker-AXS D8 Advance powder X-ray diffractometer (Bruker-AXS, Karlsruhe, Germany). The specimen holder was rotated in the zO plane at 20 rpm during measurement. The measurement conditions were as follows: Radiation: Cu Ka of wavelength 1.54A , Source 40 kV / 40 mA, divergence slit 0.6 mm, detector: Vantec-1 anti- scattering slit 5.59 mm, detector slit 10.28 mm, start angle 3°2Theta, end angle 55°2Theta, Step 0.017° 2Theta. Raw data were evaluated using the program EVA (Brulcer-AXS, Karlsruhe, Germany).
Differential scanning calorimetry (DSC)
A Mettler Toledo 822e DSC instrument was used to record the DSC curves. A sample amount of approx. 3.6 mg was placed in the calorimeter cell and heated from 30°C to 300°C with a rate of 10°C/min and a nitrogen flow of 50 ml/min.
Example 1 : Preparing of Tapentadol Free Base
Methoxy-Tapentadol hydrochloride (1 eq) was set free as Tapentadol base with 8 eq aqueous hydrobromic acid (47%) under reflux and subsequently sodium bicarbonate was added until pH 8 to 9 was reached. The solution was extracted several times with ethyl acetate. The combined organic phases were dried over sodium sulphate and distilled under reduced pressure.
Example 2: Preparation of Tapentadol hydrobromide
Tapentadol base (0.52 g, 2.35 mmol) was dissolved in acetone (5 ml) at room temperature. To this solution, aqueous hydrobromic acid (47 wt.%, 1.21 g, 7 mmol) was added and the mixture was thereafter kept in the fumehood for 3 days in an open flask. A solid precipitate formed and was separated out and filtered. The solid material was washed with acetone, and dried overnight at 40 mbars and 40°C yielding tapentadol hydrobromide 0.38 g crystals (1.3 mmol, 53.5 %yield).
Example 3: Preparation of Tapentadol free base from Tapentadol hydrobromide
To a solution of Tapentadol hydrobromide dissolved in a minimum amount of water, ethyl acetate was added. Then sodium bicarbonate was added until pH 8 to 9 was reached. The organic phase was separated. The aqueous phase was extracted several times with ethyl acetate. The combined organic phases were washed with water, dried over sodium sulphate and distilled under reduced pressure. To the oily residue, n-Hexane was added and the white solid that was formed was then filtered off.
Example 4: Preparation of Tapentadol hydrochloride from Tapentadol hydrobromide Tapentadol hydrobromide was dissolved in acetone. Gaseous hydrogen chloride was bubbled through this clear solution, and the precipitate that formed was then filtered off.
Example 5: Preparation of crystalline Tapentadol hydrobromide
Tapentadol base (0.3 g, 1.36 mmol) was suspended in 0.5 mL aqueous hydrobromic acid (47 wt.%). The suspension was warmed for 20 minutes and the warm solution was filtered. The clear solution was concentrated under reduced pressure to give an oily residue. Once at room temperature, crystals of Tapentadol hydrobromide appeared. Example 6: Preparation of Tapentadol Hydrobromide
Tapentadol base (1 eq) was dissolved in 2-butanone at room temperature. To this solution, 1 eq of trimethylsilyl bromide and leq of water were added. Tapentadol hydrobromide crystallized overnight in an open flask resultmg in a solid form, which did not undergo polymorphic conversion.
Comparative Example 7: Preparation of Tapentadol Hydrochloride
Tapentadol base (1 eq) was dissolved in 2-butanone at room temperature. To this solution, 1 eq of trimethylsilyl chloride and leq of water were added, whereupon Tapentadol hydrochloride crystallized. Depending on ambient conditions, either polymorphic Form A or Form B or mixtures thereof were obtained.
Example 8: Preparation of Tapentadol Salts
Tapentadol base (1 eq) was dissolved in an organic solvent selected from acetone, hexane, 2-butanone, diethylether, and butanol. An acid (1 eq) selected from the table below was dissolved in the same solvent. The two solutions were combined and heated to about
60°C for about 15 minutes. The reaction was then allowed to cool to room temperature. The solvent was slowly evaporated.
The reaction of Tapentadol free base and hydrobromic acid produced the
hydrobromide salt of Tapentadol. The reaction of Tapentadol free base with phosphoric acid produced the phosphate salt of Tapentadol. The phosphate salt was filtered as a solid, but became liquid a few seconds later. The sulphuric salt of Tapentadol could not be isolated.
The reaction of Tapentadol free base with the other acids resulted in a bitumen.
Figure imgf000008_0001
Figure imgf000009_0001

Claims

What is Claimed is:
1. Tapentadol hydrobromide.
2. The Tapentadol hydrobromide according to claim 1 , wherein the Tapentadol
hydrobromide is crystalline.
3. The crystalline Tapentadol hydrobromide according to claim 2, characterized by data selected from: a powder XRD partem with peaks at 9.9, 14.3, 15.3, 19.1 and 20.9 + 0.2° 20; a powder XRD pattern as depicted in Figure 1 ; a DSC thermogram depicted in
Figure 2; and any combination thereof.
4. A pharmaceutical composition comprising Tapentadol hydrobromide according to any of claims 1 to 3, and at least one pharmaceutically acceptable excipient.
5. A method for treating moderate to severe pain, comprising administering the
pharmaceutical composition according to claim 4 to a subject suffering from the moderate to severe pain.
6. Use of Tapentadol hydrobromide according to any of claims 1 to 3 for the preparation of a pharmaceutical composition.
7. Use of Tapentadol hydrobromide according to any one of claims 1 to 3 for the
treatment of moderate to severe pain.
8. Use of Tapentadol hydrobromide according to any one of claims 1 to 3 for the
manufacture of a medicament for the treatment of moderate to severe pain.
9. Use of Tapentadol hydrobromide or at least one crystalline form thereof according to any one of claims 1 to 3 for the preparation of Tapentadol free base or a salt of the free base, wherein said salt of the free base is not Tapentadol hydrobromide.
10. Use of Tapentadol hydrobromide, or at least one crystalline form thereof, according to any one of claims 1 to 3 for the preparation of Tapentadol hydrochloride.
PCT/US2011/055893 2010-10-12 2011-10-12 Tapentadol hydrobromide and crystalline forms thereof WO2012051246A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39230810P 2010-10-12 2010-10-12
US61/392,308 2010-10-12

Publications (1)

Publication Number Publication Date
WO2012051246A1 true WO2012051246A1 (en) 2012-04-19

Family

ID=44872620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/055893 WO2012051246A1 (en) 2010-10-12 2011-10-12 Tapentadol hydrobromide and crystalline forms thereof

Country Status (1)

Country Link
WO (1) WO2012051246A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013120466A1 (en) * 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
WO2015075678A1 (en) * 2013-11-21 2015-05-28 Unimark Remedies Ltd. A novel process for the preparation of 1-phenyl-3-aminopropane derivatives
WO2015117576A1 (en) 2014-02-04 2015-08-13 Zentiva, K.S. A solid form of tapentadol maleate and a method of its preparation
GB2523089A (en) * 2014-02-12 2015-08-19 Azad Pharmaceutical Ingredients Ag Stable polymorph form B of tapentadol hydrochloride
WO2017085734A1 (en) * 2015-11-17 2017-05-26 Msn Laboratories Private Limited Crystalline forms of tapentadol salts and process for preparation thereof
WO2017182438A1 (en) 2016-04-19 2017-10-26 Ratiopharm Gmbh Crystalline tapentadol phosphate
EP3636629A1 (en) 2010-07-23 2020-04-15 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
DE202021100040U1 (en) 2020-07-24 2021-08-16 Grünenthal GmbH Ethyl cellulose-coated particles containing a salt of tapentadol and phosphoric acid
EP3875077A1 (en) 2020-03-02 2021-09-08 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
EP3875080A1 (en) 2020-03-02 2021-09-08 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
WO2021175773A1 (en) 2020-03-02 2021-09-10 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693475A1 (en) 1994-07-23 1996-01-24 Grünenthal GmbH 1-Phenyl-3-dimethylamino-propane derivatives having pharmacological activity
EP1390023A2 (en) 2001-02-28 2004-02-25 Grünenthal GmbH Pharmaceutical salts
EP1612203A1 (en) 2004-06-28 2006-01-04 Grünenthal GmbH Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
WO2008110323A1 (en) 2007-03-12 2008-09-18 Grünenthal GmbH Use of 1-phenyl-3-dimethylamino-propane compounds for the therapy of neuropathy pain
WO2009071310A1 (en) 2007-12-07 2009-06-11 Grünenthal GmbH Crystalline modifications of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl -propyl)-phenol
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
WO2010096045A1 (en) * 2008-10-30 2010-08-26 Nectid, Inc. Novel and potent tapentadol dosage forms
US20110071120A1 (en) * 2009-09-22 2011-03-24 Actavis Group Ptc Ehf Solid state forms of tapentadol salts

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693475A1 (en) 1994-07-23 1996-01-24 Grünenthal GmbH 1-Phenyl-3-dimethylamino-propane derivatives having pharmacological activity
US6248737B1 (en) 1994-07-23 2001-06-19 Gruenenthal Gmbh 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
EP1390023A2 (en) 2001-02-28 2004-02-25 Grünenthal GmbH Pharmaceutical salts
EP1612203A1 (en) 2004-06-28 2006-01-04 Grünenthal GmbH Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
WO2008110323A1 (en) 2007-03-12 2008-09-18 Grünenthal GmbH Use of 1-phenyl-3-dimethylamino-propane compounds for the therapy of neuropathy pain
WO2009071310A1 (en) 2007-12-07 2009-06-11 Grünenthal GmbH Crystalline modifications of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl -propyl)-phenol
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
WO2010096045A1 (en) * 2008-10-30 2010-08-26 Nectid, Inc. Novel and potent tapentadol dosage forms
US20110071120A1 (en) * 2009-09-22 2011-03-24 Actavis Group Ptc Ehf Solid state forms of tapentadol salts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WADE W E ET AL: "Tapentadol hydrochloride: A centrally acting oral analgesic", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, vol. 31, no. 12, 1 December 2009 (2009-12-01), pages 2804 - 2818, XP026872214, ISSN: 0149-2918, [retrieved on 20100112] *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3636629A1 (en) 2010-07-23 2020-04-15 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
EP3656765B1 (en) 2010-07-23 2021-04-14 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
WO2013120466A1 (en) * 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
WO2015075678A1 (en) * 2013-11-21 2015-05-28 Unimark Remedies Ltd. A novel process for the preparation of 1-phenyl-3-aminopropane derivatives
WO2015117576A1 (en) 2014-02-04 2015-08-13 Zentiva, K.S. A solid form of tapentadol maleate and a method of its preparation
GB2523089A (en) * 2014-02-12 2015-08-19 Azad Pharmaceutical Ingredients Ag Stable polymorph form B of tapentadol hydrochloride
EP3377049B1 (en) 2015-11-17 2021-01-06 MSN Laboratories Private Limited Crystalline forms of tapentadol salts and process for preparation thereof
WO2017085734A1 (en) * 2015-11-17 2017-05-26 Msn Laboratories Private Limited Crystalline forms of tapentadol salts and process for preparation thereof
EP3377049A4 (en) * 2015-11-17 2019-06-12 MSN Laboratories Private Limited Crystalline forms of tapentadol salts and process for preparation thereof
WO2017182438A1 (en) 2016-04-19 2017-10-26 Ratiopharm Gmbh Crystalline tapentadol phosphate
EP3653599A1 (en) 2016-04-19 2020-05-20 ratiopharm GmbH Crystalline tapentadol phosphate
EP3819287A1 (en) 2016-04-19 2021-05-12 ratiopharm GmbH Amorphous tapentadol phosphate
EP3875077A1 (en) 2020-03-02 2021-09-08 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
EP3875080A1 (en) 2020-03-02 2021-09-08 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
EP3875079A1 (en) 2020-03-02 2021-09-08 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
WO2021175773A1 (en) 2020-03-02 2021-09-10 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
DE202021003994U1 (en) 2020-03-02 2022-04-12 Grünenthal GmbH Extended release dosage form of tapentadol phosphoric acid salt
DE202021100040U1 (en) 2020-07-24 2021-08-16 Grünenthal GmbH Ethyl cellulose-coated particles containing a salt of tapentadol and phosphoric acid
DE202021100039U1 (en) 2020-07-24 2021-09-30 Grünenthal GmbH Ethyl cellulose-coated particles containing a salt of tapentadol and phosphoric acid
DE102021119130A1 (en) 2020-07-24 2022-01-27 Grünenthal GmbH Ethylcellulose-coated particles containing a salt of tapentadol and phosphoric acid

Similar Documents

Publication Publication Date Title
WO2012051246A1 (en) Tapentadol hydrobromide and crystalline forms thereof
EP3150602B1 (en) Crystalline forms of a purine derivative
RU2663663C2 (en) Salt of omecamtiv mecarbil and process for preparing same
US8703967B2 (en) Crystal form of sunitinib malate
KR20180030964A (en) The co-crystals of ibrutinib and carboxylic acid
EP2753616A1 (en) Crystalline forms of afatinib di-maleate
US9221815B2 (en) Solid state form of vemurafenib choline salt
US20160354351A1 (en) Solid state forms of vemurafenib hydrochloride
EP3430004B1 (en) Solid state forms of nilotinib salts
US20230042479A1 (en) New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
US20220002302A1 (en) Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
WO2013181251A9 (en) Crizotinib hydrochloride salt in crystalline
US20200283381A1 (en) Solid state forms of elafibranor
EP2771312A1 (en) Agomelatine-urea complex and crystalline forms thereof
WO2012071524A1 (en) Arylsulfonate salts of fingolimod and processes for preparation thereof
EP3976598B1 (en) Selective histamine h3 antagonist acid addition salts and process for the preparation thereof
EP3397618A1 (en) Process for making crystalline form a of gefitinib
CA3171894A1 (en) Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid
WO2018115181A1 (en) New salt of ivabradine and uses thereof
CN117396460A (en) Solid forms of (R) -oxybutynin D-malate
WO2017035170A1 (en) Solid state forms of cediranib maleate
TW201329024A (en) Novel crystal form of (2S)-2-amino-3-hydroxy-N-[2-methoxy-2-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide and method of preparation thereof
WO2015067223A1 (en) L-tartrate salt of (1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl) acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile and process for preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11773369

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11773369

Country of ref document: EP

Kind code of ref document: A1